Deadly Diabetes Medication
Onglyza® and Kombiglyze XR® Linked to Heart Failure
In 2016, the FDA issued a statement warning of for diabetes patients taking Onglyza® and Kombiglyze XR® which belong to a class of diabetes drugs known as DPP-4 inhibitors manufactured by AstraZenca.
The FDA approved Onglyza® in 2009, and Kombiglyze XR® in 2010. Since their approval, the drugs have been heavily scrutinized after studies linked them to these serious heart complications.
Saxagliptin an active ingredient in both medications a, has been liked to an increased risk for heart failure, cardiac problems a cardiac related deaths.
Following that announcement of this risk, there were over 100 lawsuits filed by patients who experienced complications while taking Onglyza and Kombiglyze XR against AstraZenca; the manufacturer. These cases have been compiled in a multi-district litigation class action lawsuit this is currently pending trial.
A recent study has also shown that Onglyza® & Kombiglyze XR® increase the Rate of hospitalization from heart failure in diabetes patients by 27%.
As a result of AstraZenca failing to properly warn patients and doctors of these severe risk Onglyza® and Kombiglyze XR®, you may be entitled to compensation. If you or your loved one has ever suffered significant health problems, emotional and physical stress, as well as financial burdens (medical bills, doctor or hospital visits, time off work, necessary treatments and/or procedures).
If you, or someone you know, have experienced any of the aforementioned side effects as a result of taking a DPP-4 inhibitor diabetes drug,
We encourage you to call us or contact us online or call today !